m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03168)
Name
3-Benzenesulfonyl-heptanoic acid hydroxyamide
Synonyms
CHEMBL263501; 3-Benzenesulfonyl-heptanoic acid hydroxyamide; BDBM50089196
    Click to Show/Hide
Status
Investigative
Structure
Formula
C13H19NO4S
InChI
1S/C13H19NO4S/c1-2-3-7-12(10-13(15)14-16)19(17,18)11-8-5-4-6-9-11/h4-6,8-9,12,16H,2-3,7,10H2,1H3,(H,14,15)
InChIKey
TUUMURVUDGZZQZ-UHFFFAOYSA-N
PubChem CID
9838786
TTD Drug ID
D08ELY
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-1 (MMP-1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for 3-Benzenesulfonyl-heptanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Benzenesulfonyl-heptanoic acid hydroxyamide through regulating the expression of Matrix metalloproteinase-1 (MMP-1). [1], [2]
Matrix metalloproteinase-12 (MMP-12)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 3-Benzenesulfonyl-heptanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Benzenesulfonyl-heptanoic acid hydroxyamide through regulating the expression of Matrix metalloproteinase-12 (MMP-12). [2], [3]
Matrix metalloproteinase-13 (MMP-13)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 3-Benzenesulfonyl-heptanoic acid hydroxyamide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-Benzenesulfonyl-heptanoic acid hydroxyamide through regulating the expression of Matrix metalloproteinase-13 (MMP-13). [2], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 3-Benzenesulfonyl-heptanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Benzenesulfonyl-heptanoic acid hydroxyamide through regulating the expression of Matrix metalloproteinase-13 (MMP-13). [2], [5]
References
Ref 1 METTL3 involves the progression of osteoarthritis probably by affecting ECM degradation and regulating the inflammatory response. Life Sci. 2021 Aug 1;278:119528. doi: 10.1016/j.lfs.2021.119528. Epub 2021 Apr 21.
Ref 2 Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31. doi: 10.1021/jm000018k.
Ref 3 The aberrant cross-talk of epithelium-macrophages via METTL3-regulated extracellular vesicle miR-93 in smoking-induced emphysema. Cell Biol Toxicol. 2022 Feb;38(1):167-183. doi: 10.1007/s10565-021-09585-1. Epub 2021 Mar 4.
Ref 4 FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13. Exp Cell Res. 2020 Apr 1;389(1):111894. doi: 10.1016/j.yexcr.2020.111894. Epub 2020 Feb 6.
Ref 5 METTL3 promotes experimental osteoarthritis development by regulating inflammatory response and apoptosis in chondrocyte. Biochem Biophys Res Commun. 2019 Aug 13;516(1):22-27. doi: 10.1016/j.bbrc.2019.05.168. Epub 2019 Jun 8.